Is AstraZeneca (LSE:AZN) Still Cheap After Its 83% Five Year Run?

AstraZeneca has quietly put up a strong share price record in recent years, and the question now is whether that performance is fully backed by the cash the business is expected to generate. With a Discounted Cash Flow (DCF) view available, the focus turns to how the current market price lines up against the value implied by those future cash streams.

• Over the past 5 years, AstraZeneca has delivered an 83.0% share price gain, which raises the stakes for whether its future cash flows can support today’s valuation.
• Oncology sales growth and a series of acquisitions in areas like vaccines and targeted therapies may support expectations for larger and more durable cash flows, but they can also mean higher upfront investment and a longer wait for those cash flows to materialise.
• Prefer to judge AstraZeneca on earnings? See what AstraZeneca's 26.0x P/E says about the price.

The issue now is whether AstraZeneca's current share price fairly reflects the intrinsic value suggested by its cash flows when viewed through a Discounted Cash Flow model.

For context on how AstraZeneca's cash flow story compares to other opportunities in the market, it can help to line it up next to 9 healthcare AI stocks.

Is AstraZeneca a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here uses AstraZeneca's own cash generation to anchor the valuation. Latest twelve month free cash flow sits at about US$7.1b, and the projections assume that this cash pool grows over time rather than shrinking.

Analyst and internal estimates point to free cash flow in the low to mid US$20b range by the early 2030s, which implies a business leaning on larger cash generation rather than a one off spike. That growth path sits alongside heavy oncology investment and deals in areas like vaccines and targeted radiotherapies, so the cash story depends on those pipelines and acquisitions turning into durable franchises. Because the Discounted Cash Flow (DCF) projections put AstraZeneca's estimated intrinsic value substantially above the current share price of £139.82, the market price reflects a clear discount to what these cash flows support. The offer for Rhythm Pharmaceuticals and wider oncology deal making helps explain why some investors may still question how much of that future cash is truly locked in. Find out what AstraZeneca could be worth using our Discounted Cash Flow (DCF) estimate.

The AstraZeneca Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for AstraZeneca pick up where the valuation puzzle leaves off and spell out which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price on the Community page. Each narrative treats AstraZeneca's implied worth as a thesis about how the business could evolve that you can track over time as new data arrives.

Bulls and bears looking at AstraZeneca are reading the same pipeline but drawing very different conclusions about how much is already priced in.

Bull case: 13% undervalued

The analyst consensus Narrative on Simply Wall St argues AstraZeneca’s breadth in late stage drugs is not fully captured in the current quote.

"The company's robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular or metabolic therapies, is now underpinned by management's disclosure of 12 programs each with risk adjusted peak sales potential above US$5b and several more in the US$3b to US$5b range..."

Discover why this Narrative puts AstraZeneca at 13% undervalued.

Bear case: 16% overvalued

The bearish analyst Narrative on Simply Wall St leans on pipeline risk and capital intensity to argue the current tag already bakes in a lot of good news.

"Large scale investments in AI enabled discovery and a multi billion dollar capital build out, including a new ADC facility and expanded emerging market manufacturing, increase fixed costs..."

Explore why this Narrative puts AstraZeneca at 16% overvalued.

Before focusing on AstraZeneca's valuation, check what the risk checks are saying

Price and cash flow only tell part of the story, since Simply Wall St's broader review of AstraZeneca has also surfaced specific areas of concern that are worth checking for yourself before making any move. Take a closer look at 1 warning sign before settling on a valuation.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com